Exciting News from the EIT Health Fast Track Programme!
Great news of December 15th 2024!
CellProthera will carry out technology transfer ahead of autologous CD34+ endothelial progenitor cell clinical trials planned by...
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease...
Speaking at a press conference, CellProthera’s CEO said the company is moving into the final phase of...
Revolutionizing Cardiac Regeneration.
Positive pre-IND meeting with FDA helps position CellProthera for a U.S. and international Phase III trial for...
The long-term PERFECT observational study follows patients from successful Phase I/IIb of ProtheraCytes for the repair and...
MULHOUSE, France, and SUNNYVALE, California USA – July 8, 2024 CellProthera, a private company specializing in cell-based...
July 8, 2024—France-based CellProthera and BioCardia, Inc., which is headquartered in California, announced findings from the collaborative...
Researchers harvest stem cells from patients who have recently had a heart attack and use them to...
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following...
Positive changes in prognostic biomarkers including infarct size, left ventricular dimensions and NT-proBNP level support the anti-remodeling...
Mulhouse, France, April 23 2024 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases will...
DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on the future...
Didier HAGUENAUER – CMO – CELLPROTHERA
Upcoming clinical trials, led by stem cell pioneer Professor Takayuki Asahara, will use CellProthera’s StemXpand® and StemPack®...
CellProthera collaborates with Japanese stem cell experts at Shonan-Kamakura General Hospital (SKGH) on clinical manufacturing for upcoming...
A 20 year old promise slowly becoming a reality